A May 12 federal complaint says Hisense and VIDAA snapshot screens every half‑second, build cross‑device profiles and share them with ad‑tech and Chinese affiliates.

Atara and partner Pierre Fabre won narrow FDA guidance that could allow a resubmission for tabelecleucel; the stock spiked and the companies plan more data and follow‑up.

Philadelphia robotics firm Exyn went public in a $19.4M Nasdaq listing, a rare local tech IPO — even as SEC filings show a $75.9M accumulated deficit and limited cash.

Gradiant closed a Series E that values the Boston water-tech firm at about $2B and said it aims for an IPO in roughly 18 months as it scales into AI and semiconductor markets.

Top AI researchers say limited access to TPUs and server time at Google pushed them to found startups that can buy or control compute. The shift is reshaping Bay Area AI.

Compass Minerals and EnergyX signed an MOU to test direct lithium extraction at the Great Salt Lake, bringing roughly $400M in planned investment and reviving a shelved project.

OpenAI quietly acquired voice‑cloning startup Weights.gg, took its Replay app offline and removed a public catalog of celebrity and political voice models. The tiny team has been folded into OpenAI’s voice work.

Pittsburgh's Krystal Biotech won MHRA approval for VYJUVEK, a topical gene therapy for DEB. The company says U.K. launch timing will depend on reimbursement and payer decisions.

A massive new Nusano plant in West Valley City aims to produce 40+ radioisotopes for diagnostics and cancer therapies while adding high‑tech jobs to Utah. Reservations and supply deals are already underway.

Boston Scientific paid $1.5 billion for a roughly 34% stake in MiRus and an option to acquire the SIEGEL TAVR business, a potential fast path back into balloon‑expandable valves. The move hinges on clinical and regulatory milestones.

A new Frontiers study finds a small uptick in lung cancer incidence after COVID‑19, especially among current and former smokers, and points to the enzyme TYMP as a likely mechanism.

LSU LCMC Health Cancer Center is expanding clinical trials and precision oncology in New Orleans, adding early‑phase cellular studies and new specialists.

A JAMA Cardiology study led by UT Southwestern shows an AI‑augmented ECG screened nearly 6,000 Kenyans and reliably ruled out left‑ventricular dysfunction for most patients.